🔥Telegram İfşa

Just out in the New England Journal of Medicine! Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance NEJM nejm.org/doi/full/10.10… 5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and

2nd Latino Cancer Patient Advocate Training Program. If you qualify(or know someone that does) apply by completing the form forms.gle/9YEQmwV9yh8Axn…

Outcome of pts w Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy is partic poor: Descar-T Study ⁦Lysa Lymphoma⁩ Bispec Abs appear promising offering durable responses c.f to chemotherapy & targeted therapy ⁦Blood Advances⁩ ashpublications.org/bloodadvances/…

🚨AMPLIFIQUEMOS LA VOZ DE ANDRÉS – ES #URGENTE SALVAR SU VIDA 🚨NUEVA EPS LE NIEGA SU MEDICAMENTO VITAL 🆘 Andrés Felipe Henao Muñoz, 27 años, Andrés Felipe Henao Muñoz con enfermedad rara Inmunodeficiencia Común Variable, hipertensión pulmonar e insuficiencia cardíaca. La NUEVA EPS le ha

Well done to Claire Roddie and team for this amazing work. Many take home messages from this work -Lymphodepletion is essential for CAR-T to work -Repeat doses don't seem to work here, but more work is needed HCC_UCLH ashpublications.org/blood/article-…

Hot off the press! Lewis et al. Wonderful to see this international investigator initiated academic RCT published open access in The Lancet today Fantastic UK+Nordic collaboration #MCL #Lymsm thelancet.com/journals/lance…

Que peligro ir a la tiene local de vinilos! Nuevas adquisiciones para Octubre. Un poquito para todos los gustos! Went a bit over board at the local Vinyl store. 🫠🫠BlackSabbath Fabulosos Cadillacs John Coltrane Tears for Fears Rock a Domicilio 🌠 Alberto Marchena Jr.

Led Zeppelin performing at Kezar Stadium in San Francisco (1973)

This year’s #NobelPrize goes for the discovery of regulatory T cells (Tregs) and FOXP3. Absolutely vital discovery in the field of hematology, oncology, cellular therapy, rheumatology, neurology…all medicine! Immunology at its best!

Ven/obinu outcomes CLL13/14 - 410 pts, 56% unfit CIRS>6 or GFR<70 - no diff PFS/OS by fitness - AEs not different in fit vs unfit - inferior PFS if <70% ven dose intensity (no diff OS) Would love to see this analysis in non-trial fit/unfit cohort. #lymsm ashpublications.org/blood/article/…

Acquired factor X deficiency, a rare complication of AL amyloidosis, affects ~4.4% of patients. FX activity improves with clone-directed therapy, with greater recovery in hemCR. HDM/SCT is associated with improvements but carries bleeding risks doi.org/10.1002/ajh.70… Andrew Staron

▶️Really important analysis of #pirtobrutinib resistance in R/R #CLL from BRUIN now online in Blood Journals Portfolio Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia ashpublications.org/blood/article/…

Low-dose Nivolumab and Lenalidomide in Relapsed/Refractory Hodgkin Lym... sciencedirect.com/science/articl…. Vikram Mathews Uday Kulkarni Phaneendra Datari

Outstanding presentation by Julio Chavez on impact of novel therapies in follicular lymphoma IACH #COLYM in Paris, France 🇫🇷 Anna Sureda Mohamad Mohty Mehdi Hamadani, MD Stefano Luminari, MD

Excellent iNHL session tonight at #IACH 🇫🇷 with Stefano Luminari, MD Jessica Okosun Julio Chavez 🤩 Cc Andrew M. Evens, DO, MBA, MSc Luca Arcaini Anna Sureda

BREAKING NEWS The Norwegian Nobel Committee has decided to award the 2025 #NobelPeacePrize to Maria Corina Machado for her tireless work promoting democratic rights for the people of Venezuela and for her struggle to achieve a just and peaceful transition from dictatorship to

2 trials reinforce less is more with anti-platelet & DOACs: 1. AQUATIC (NEJM): Adding ASA to DOACs in chronic coronary syndrome = ↑ death + bleeding 2. ATIS‑NVAF (JAMA): Adding ASA to DOACs after stroke w/ concurrent Afib+ASCVD = no benefit + ⬆️ 🩸 #HemeTwitter #MedTwitter

Stop celebrating FOMO. It's a dream and this dream depresses you. Stay in the present and be happy!

Site of action of hyperuricemic drugs in the purine metabolism pathway! The hydrogen peroxide produced as a byproduct of Rasburicase activity ➡️ oxidative stress ➡️ hemolysis if G6PD deficient! 📸 DOI: 10.1056/NEJMra23009

Left: This is where it all started Right: This is where we are in 2025 💪🏽 This is what progress looks like! Trust science, trust the process 🙏🏽 Ref: 10.1056/NEJM194806032382301 Ref: 10.1056/NEJMoa2411680